A federal court has rejected a lawsuit by several drugmakers that sought to change the 340B Drug Pricing Program from an upfront payment model to a backend rebate structure.
Court rejects drugmakers replacing 340B upfront payments with rebates
A federal court has rejected a lawsuit by several drugmakers that sought to change the 340B Drug Pricing Program from an upfront payment model to a backend rebate structure.